These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 12455906)

  • 1. Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):989-93. PubMed ID: 12455906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Aug; 50(30):643-5. PubMed ID: 11787575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.
    Khromava AY; Eidex RB; Weld LH; Kohl KS; Bradshaw RD; Chen RT; Cetron MS;
    Vaccine; 2005 May; 23(25):3256-63. PubMed ID: 15837230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe.
    Bae HG; Domingo C; Tenorio A; de Ory F; Muñoz J; Weber P; Teuwen DE; Niedrig M
    J Infect Dis; 2008 Jun; 197(11):1577-84. PubMed ID: 18419548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From the Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.
    JAMA; 2002 Nov; 288(20):2533-5. PubMed ID: 12465621
    [No Abstract]   [Full Text] [Related]  

  • 6. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases.
    McMahon AW; Eidex RB; Marfin AA; Russell M; Sejvar JJ; Markoff L; Hayes EB; Chen RT; Ball R; Braun MM; Cetron M;
    Vaccine; 2007 Feb; 25(10):1727-34. PubMed ID: 17240001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yellow fever-associated viscerotropic disease in Barcelona, Spain.
    Muñoz J; Vilella A; Domingo C; Nicolas JM; de Ory F; Corachan M; Tenorio A; Gascon J
    J Travel Med; 2008; 15(3):202-5. PubMed ID: 18494699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004.
    Vellozzi C; Mitchell T; Miller E; Casey CG; Eidex RB; Hayes EB
    Am J Trop Med Hyg; 2006 Aug; 75(2):333-6. PubMed ID: 16896144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.
    Kitchener S
    Vaccine; 2004 Jun; 22(17-18):2103-5. PubMed ID: 15149765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute viscerotropic disease following vaccination against yellow fever.
    Hayes EB
    Trans R Soc Trop Med Hyg; 2007 Oct; 101(10):967-71. PubMed ID: 17669451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yellow fever vaccine-associated viscerotropic disease and death in Spain.
    Doblas A; Domingo C; Bae HG; Bohórquez CL; de Ory F; Niedrig M; Mora D; Carrasco FJ; Tenorio A
    J Clin Virol; 2006 Jun; 36(2):156-8. PubMed ID: 16597510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viscerotropic disease following yellow fever vaccination in Peru.
    Whittembury A; Ramirez G; Hernández H; Ropero AM; Waterman S; Ticona M; Brinton M; Uchuya J; Gershman M; Toledo W; Staples E; Campos C; Martínez M; Chang GJ; Cabezas C; Lanciotti R; Zaki S; Montgomery JM; Monath T; Hayes E
    Vaccine; 2009 Oct; 27(43):5974-81. PubMed ID: 19679215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case suspected for yellow fever vaccine-associated viscerotropic disease in the Netherlands.
    van de Pol EM; Gisolf EH; Richter C
    J Travel Med; 2014; 21(6):421-4. PubMed ID: 24920138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
    Rafferty E; Duclos P; Yactayo S; Schuster M
    Vaccine; 2013 Dec; 31(49):5798-805. PubMed ID: 24079979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse event reports following yellow fever vaccination.
    Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
    Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rare case of fatal yellow fever vaccine-associated viscerotropic disease.
    Gerasimon G; Lowry K
    South Med J; 2005 Jun; 98(6):653-6. PubMed ID: 16004173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
    Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
    Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases.
    Ledlie S; Ricci C; Pan C; Rojas A; Khromava A; Li L
    Vaccine; 2022 Jan; 40(5):742-751. PubMed ID: 34996642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.